The superior effects of obinutuzumab seen in the laboratory have been confirmed in clinical trials and, in 2013, the drug was the first drug to be awarded Breakthrough Therapy Designation by the ...

Reply to: “Breast Cancer Screening Interval: Effects of Proportions and Biases on Benefits” and “Annual Versus Biennial Mammographic Screening” The article by Davids et al entitled “A Phase II Study ...

A third arm evaluating acalabrutinib-venetoclax plus intravenous obinutuzumab (Gazyva) also topped chemoimmunotherapy when it came to PFS, with a 3-year rate of 83.1% (HR 0.42, 95% CI 0.30-0.59 ...

Imbruvica plus venetoclax significantly extends PFS in untreated CLL patients compared to chlorambucil plus Gazyva, with 52 months versus 31 months. The combination therapy shows durable efficacy and ...